Literature DB >> 15480945

Dynamic contrast-enhanced MRI using macromolecular contrast media for monitoring the response to isolated limb perfusion in experimental soft-tissue sarcomas.

A Preda1, P A Wielopolski, T L M Ten Hagen, M van Vliet, J F Veenland, G Ambagtsheer, S T van Tiel, M W Vogel, A M M Eggermont, G P Krestin, C F van Dijke.   

Abstract

The objective of this study was to evaluate the potential of dynamic contrast-enhanced MRI for quantitative characterization of tumor microvessels and to assess the microvascular changes in response to isolated limb perfusion with TNF-alpha and melphalan. Dynamic contrast-enhanced MRI was performed in an experimental cancer model, using a macromolecular contrast medium, albumin-(Gd-DTPA)45. Small fragments of BN 175, a soft-tissue sarcoma, were implanted in 11 brown Norway (BN) rats. Animals were assigned randomly to a control (Haemaccel) or drug-treated group (TNF-alpha/melphalan). MRI was performed at baseline and 24 h after ILP. The transendothelial permeability (K(PS)) and the fractional plasma volume (fPV) were estimated from the kinetic analysis of MR data using a two-compartment bi-directional model. K(PS) and fPV decreased significantly in the drug-treated group compared to baseline (p<0.05). In addition, K(PS) post therapy was significantly lower (p<0.05) in the drug-treated group than in the control group. There was no significant difference in fPV between the drug-treated and the control group after therapy. Tumor microvascular changes in response to isolated limb perfusion can be determined after 24 h by dynamic contrast-enhanced MRI. The data obtained in this experimental model suggest possible applications in the clinical setting, using the appropriate MR contrast agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15480945     DOI: 10.1007/s10334-004-0050-z

Source DB:  PubMed          Journal:  MAGMA        ISSN: 0968-5243            Impact factor:   2.310


  35 in total

1.  MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to histopathology.

Authors:  K Turetschek; E Floyd; T Helbich; T P Roberts; D M Shames; M F Wendland; W O Carter; R C Brasch
Journal:  J Magn Reson Imaging       Date:  2001-09       Impact factor: 4.813

2.  Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging.

Authors:  G Brix; W Semmler; R Port; L R Schad; G Layer; W J Lorenz
Journal:  J Comput Assist Tomogr       Date:  1991 Jul-Aug       Impact factor: 1.826

Review 3.  Assessing tumor angiogenesis using macromolecular MR imaging contrast media.

Authors:  R Brasch; C Pham; D Shames; T Roberts; K van Dijke; N van Bruggen; J Mann; S Ostrowitzki; O Melnyk
Journal:  J Magn Reson Imaging       Date:  1997 Jan-Feb       Impact factor: 4.813

4.  MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation.

Authors:  K Turetschek; S Huber; E Floyd; T Helbich; T P Roberts; D M Shames; K S Tarlo; M F Wendland; R C Brasch
Journal:  Radiology       Date:  2001-02       Impact factor: 11.105

5.  Toxic effect of tumor necrosis factor on tumor vasculature in mice.

Authors:  N Watanabe; Y Niitsu; H Umeno; H Kuriyama; H Neda; N Yamauchi; M Maeda; I Urushizaki
Journal:  Cancer Res       Date:  1988-04-15       Impact factor: 12.701

6.  Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors.

Authors:  H B Larsson; M Stubgaard; J L Frederiksen; M Jensen; O Henriksen; O B Paulson
Journal:  Magn Reson Med       Date:  1990-10       Impact factor: 4.668

7.  The efficacy of combined treatment with recombinant human tumor necrosis factor-alpha and 5-fluorouracil is dependent on the development of capillaries in tumor.

Authors:  T Manda; F Nishigaki; S Mukumoto; K Masuda; T Nakamura; K Shimomura
Journal:  Eur J Cancer       Date:  1990-02       Impact factor: 9.162

8.  Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study.

Authors:  D Liénard; A M Eggermont; H Schraffordt Koops; B B Kroon; F Rosenkaimer; P Autier; F J Lejeune
Journal:  Melanoma Res       Date:  1994-03       Impact factor: 3.599

9.  Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor.

Authors:  J R Gamble; J M Harlan; S J Klebanoff; M A Vadas
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

10.  Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor.

Authors:  G Camussi; F Bussolino; G Salvidio; C Baglioni
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

View more
  7 in total

1.  Tumor microvasculature observed using different contrast agents: a comparison between Gd-DTPA-Albumin and B-22956/1 in an experimental model of mammary carcinoma.

Authors:  Federico Boschi; Pasquina Marzola; Marco Sandri; Elena Nicolato; Mirco Galiè; Silvia Fiorini; Flavia Merigo; Vito Lorusso; Linda Chaabane; Andrea Sbarbati
Journal:  MAGMA       Date:  2008-03-04       Impact factor: 2.310

2.  PWI-MRI and contrast extravasation in brain AVM help to estimate angiogenic activity.

Authors:  Guillaume Saliou; Timo Krings; Dik R Rutgers; Frederique Toulgoat; Augustin Ozanne; Pierre Lasjaunias; Denis Ducreux
Journal:  Neuroradiology       Date:  2011-05-12       Impact factor: 2.804

3.  Multiparametric Assessment of Treatment Response in High-Grade Soft-Tissue Sarcomas with Anatomic and Functional MR Imaging Sequences.

Authors:  Theodoros Soldatos; Shivani Ahlawat; Elizabeth Montgomery; Majid Chalian; Michael A Jacobs; Laura M Fayad
Journal:  Radiology       Date:  2015-09-21       Impact factor: 11.105

Review 4.  Musculoskeletal tumors: how to use anatomic, functional, and metabolic MR techniques.

Authors:  Laura M Fayad; Michael A Jacobs; Xin Wang; John A Carrino; David A Bluemke
Journal:  Radiology       Date:  2012-11       Impact factor: 11.105

5.  Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology: Theory, Data Acquisition, Analysis, and Examples.

Authors:  Thomas E Yankeelov; John C Gore
Journal:  Curr Med Imaging Rev       Date:  2009-05-01

6.  Evaluation of Soft Tissue Sarcoma Response to Preoperative Chemoradiotherapy Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging.

Authors:  Wei Huang; Brooke R Beckett; Alina Tudorica; Janelle M Meyer; Aneela Afzal; Yiyi Chen; Atiya Mansoor; James B Hayden; Yee-Cheen Doung; Arthur Y Hung; Megan L Holtorf; Torrie J Aston; Christopher W Ryan
Journal:  Tomography       Date:  2016-12

7.  Descriptive analysis of MRI functional changes occurring during reduced dose radiotherapy for myxoid liposarcomas.

Authors:  Evanthia Kousi; Christina Messiou; Aisha Miah; Matthew Orton; Rick Haas; Khin Thway; Georgina Hopkinson; Shane Zaidi; Myles Smith; Elizabeth Barquin; Eleanor Moskovic; Nicos Fotiadis; Dirk Strauss; Andrew Hayes; Maria A Schmidt
Journal:  Br J Radiol       Date:  2021-10-01       Impact factor: 3.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.